World News

The new site will complement RayzeBio’s existing 77,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, located about 20 miles southwest of Whitestown.

These therapies can require multiple stages, including DNA starting materials, RNA production, targeted delivery technologies, formulation, analytical testing and scalable drug product manufacturing.

The two firms launched Metsera in 2022, and the biotech emerged from stealth in 2024 after securing US$290 million in financing.

The antisense oligonucleotide (ASO) medicine, which GSK will market in Japan as Hibsago, is approved for adults with hepatitis B who meet specified viral markers.

McKesson expects the acquisition to strengthen its oncology and multi-specialty strategy while broadening the services it provides to biopharmaceutical companies.

Biohaven is currently evaluating the therapy in the Phase II/III RISE3 study, with results expected in the second half of 2026.

Hanmi is developing the HM17321 therapy as a potential first-in-class treatment that could promote weight loss while helping preserve lean body mass.

The agreement builds on Peking University’s longstanding involvement in global health research and public health capacity development.

Seralutinib is an investigational treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The test is now being evaluated for use in Sub-Saharan Africa, where researchers hope it could become the first validated rapid diagnostic test for iron deficiency.